Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib Schedules in ER+/HER2- Advanced Breast Cancer
NCT02630693Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Apr 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Progression-Free Survival at 2 years. Started Apr 2016; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02630693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630693.